Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer

INDIANAPOLIS, April 20, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced additional results from its global, randomized, double-blind, placebo-controlled Phase 3 RANGE trial evaluating CYRAMZA® (ramucirumab) in combination with docetaxel in patients with locally...